Single-center experience on renal transplantation in primary focal and segmental glomerulosclerosis using hematopoietic stem cell transplantation in thymus, bone marrow, portal and peripheral circulation
المؤلفون المشاركون
Shah, Pankaj R.
Vanikar, Aruna V.
Trivedi, Hargovind L.
Patel, Rashmi D.
Kanodia, Kamal V.
Trivedi, Varsha B.
Modi, Pranjal R.
Davi, Shruti D.
Singhai, Atin M.
Shah, Veena R.
Shankar, V.
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 24، العدد 1 (28 فبراير/شباط 2013)، ص ص. 15-21، 7ص.
الناشر
تاريخ النشر
2013-02-28
دولة النشر
السعودية
عدد الصفحات
7
التخصصات الرئيسية
الموضوعات
الملخص EN
Recurrence of primary focal segmental glomerulosclerosis (FSGS) is an important cause of graft loss after renal transplantation (RTx).
We report our experience in 34 patients with primary FSGS who underwent RTx between April 1999 and June 2009, using hematopoietic stem cell transplantation (HSCT).
They belonged to four groups : group 1 (n = 12) received high-dose HSCT in periphery, thymus, bone-marrow, and portal circulation with low-dose non-myeloablative conditioning ; group 2 (n = 7) was modified with HSCT without marrow / thymic infusion ; and group 3 (n = 3) received HSCT and proteasome inhibitor Bortezomib replacing conditioning.
Group 4 (n = 12), were controls who opted for RTx under standard triple-drug immunosuppression.
Patient / donor demographics were comparable in all.
No recurrence was noted in group 1 with mean follow-up of 8.1 years, whereas 28.6 % of group 2, 33.3 % of group 3, and 36.4 % of group 4 had recurrence over mean followup of 2.6, 1.1, and 6.5 years, respectively.
Mean serum creatinine was 1.62, 1.69, 1.41, and 1.73 mg %, respectively.
Rejections were noted in 41.7 %, 28.6 %, 0 %, and 45.5 % grafts, respectively.
Groups 1 and 4 had 25 % patient loss each, group 2 had 28.6 % loss, and no loss was observed in group 3.
Graft loss was noted in 33.3 % in group 1, 14.3 % in group 2, nil in group 3, and 16.7 % in the last group. Recurrent FSGS was prevented in RTx with HSCT in thymic, marrow infusion under low-dose nonmyeloablative conditioning compared to controls and Bortezomib group, thus suggesting potential role of central tolerance in FSGS.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Vanikar, Aruna V.& Trivedi, Hargovind L.& Shah, Pankaj R.& Kanodia, Kamal V.& Patel, Rashmi D.& Modi, Pranjal R.…[et al.]. 2013. Single-center experience on renal transplantation in primary focal and segmental glomerulosclerosis using hematopoietic stem cell transplantation in thymus, bone marrow, portal and peripheral circulation. Saudi Journal of Kidney Diseases and Transplantation،Vol. 24, no. 1, pp.15-21.
https://search.emarefa.net/detail/BIM-329809
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Vanikar, Aruna V.…[et al.]. Single-center experience on renal transplantation in primary focal and segmental glomerulosclerosis using hematopoietic stem cell transplantation in thymus, bone marrow, portal and peripheral circulation. Saudi Journal of Kidney Diseases and Transplantation Vol. 24, no. 1 (2013), pp.15-21.
https://search.emarefa.net/detail/BIM-329809
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Vanikar, Aruna V.& Trivedi, Hargovind L.& Shah, Pankaj R.& Kanodia, Kamal V.& Patel, Rashmi D.& Modi, Pranjal R.…[et al.]. Single-center experience on renal transplantation in primary focal and segmental glomerulosclerosis using hematopoietic stem cell transplantation in thymus, bone marrow, portal and peripheral circulation. Saudi Journal of Kidney Diseases and Transplantation. 2013. Vol. 24, no. 1, pp.15-21.
https://search.emarefa.net/detail/BIM-329809
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 21
رقم السجل
BIM-329809
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر